Sam Huang Portfolio
Invests via Checkpoint Capital L.P. | Managed by Sam Huang
Invests via Checkpoint Capital L.P.
Managed by Sam Huang
Automatically Tracked
Sam Huang Profile
Silicon Valley–connected investor and operator focused on growth-stage AI and enterprise SaaS markets. Sam Huang is an entrepreneur-turned-investor with operating experience scaling product and GTM teams across cloud software and developer tooling. He evaluates opportunities at the intersection of AI infrastructure and workflow automation, advising boards on go-to-market strategy, metrics-driven scaling and capital strategy. Prior roles span startup founding, early-stage investing, and corporate development; speaks to LPs and strategic acquirers.
Silicon Valley–connected investor and operator focused on growth-stage AI and enterprise SaaS markets. Sam Huang is an entrepreneur-turned-investor with operating experience scaling product and GTM teams across cloud software and developer tooling. He evaluates opportunities at the intersection of AI infrastructure and workflow automation, advising boards on go-to-market strategy, metrics-driven scaling and capital strategy. Prior roles span startup founding, early-stage investing, and corporate development; speaks to LPs and strategic acquirers.
Investment Philosophy & Strategy
Operator-investor approach focused on growth-stage AI and enterprise SaaS, prioritizing companies at the intersection of AI infrastructure and workflow automation. Thesis-driven capital allocation emphasizes metrics-led go-to-market scaling, unit-economics improvement and board-level operational support. Prefers conviction-sized, mid-to-long-term growth investments in cloud software and developer tooling, deploying capital to accelerate product-market fit, topline expansion and disciplined margin improvement.
Operator-investor approach focused on growth-stage AI and enterprise SaaS, prioritizing companies at the intersection of AI infrastructure and workflow automation. Thesis-driven capital allocation emphasizes metrics-led go-to-market scaling, unit-economics improvement and board-level operational support. Prefers conviction-sized, mid-to-long-term growth investments in cloud software and developer tooling, deploying capital to accelerate product-market fit, topline expansion and disciplined margin improvement.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
151.49%
Gain +2.52%
Monthly
2.98%
Yearly
42.21%
Drawdown
37.51%
$387.84M
Equity
Holdings
$387.84M
Investment
$240.39M
$188.47M
Profit +$6.03M
Realized
$41.02M
Unrealized
$147.45M
Dividends
$0
Goals
Avg. 49% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
2.52%
Profit
$6.03M
Win %
89%
This Week
Compared To Last Week
Gain
1.3%
Profit
$4.97M
Win %
89%
This Month
Compared to last month
Gain
3.32%
Profit
$12.45M
Win %
89%
This Year
Compared to last year
Gain
-0.49%
Profit
-$1.92M
Win %
85%
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 131 | Longs Won 87/131 66% | Profit Factor 4.52 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4.63M |
| Average Win $2.78M | Best Trade (Aug 15) $33.33M | Sharpe Ratio -9.13 |
| Average Loss -$1.22M | Worst Trade (Mar 30) -$13.08M | Z-Score 2.57 (98.98%) |
| Commissions $0 | Avg. Trade Length 9m 1w 1d | Expectancy $1.44M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.43% |
| Consecutive Losing Trades | 319 | 287 | 255 | 223 | 191 | 159 | 128 | 96 | 64 | 32 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
 ARGX argenx SE American Depositary Receipt | 131,283 | $66.37M | $111.76M | - | $45.39M | 68.39% | -0.659% |
 CYTK Cytokinetics, Incorporated | 475,000 | $36.28M | $35.21M | - | -$1.07M | -2.94% | +0.926% |
 IRON Disc Medicine Inc. | 240,125 | $15.39M | $18.93M | - | $3.54M | 23.02% | -1.462% |
 RVMD Revolution Medicines Inc. | 410,353 | $39.37M | $83.59M | - | $44.22M | 112.31% | +0.847% |
 RYTM Rhythm Pharmaceuticals Inc. | 1.19M | $81.92M | $136.96M | - | $55.04M | 67.2% | -0.465% |
 TRVI Trevi Therapeutics Inc. | 75,000 | $1.06M | $1.38M | - | $321,750 | 30.28% | +1.708% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Sam Huang?
The largest contributions to the portfolio's profits come from the following stocks: Rhythm Pharmaceuticals Inc - $20.64M, argenx SE American Depositary Receipt - $15.57M, Revolution Medicines Inc - $10.47M, Septarna Inc - $9.72M, and Protagonist Therapeutics Inc - $8.09M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Corcept Therapeutics Incorporated - $13.82M, Cytokinetics, Incorporated - $9.06M, Phathom Pharmaceuticals Inc - $7.78M, TScan Therapeutics Inc - $4.52M, and Avadel Pharmaceuticals plc - $3.04M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Sam Huang's monthly returns?
Sam Huang's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Sam Huang's strategy be considered aggressive or moderate?
Sam Huang's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Sam Huang's strategy?
Sam Huang's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
